title: Osteoporosis screening and treatment in women with schizophrenia: a controlled study.
abstract: OBJECTIVE
  As patients with a major psychiatric disorder such as schizophrenia generally are less likely to have their medical illnesses diagnosed and medically managed, we investigated whether osteoporosis screening, prevention management, and/or drug therapy (i.e., clinical services for osteoporosis) are provided consistently to both women with schizophrenia and those without the disease.
  
  
  METHODS
  Retrospective medical record review.
  
  
  METHODS
  Three Midwest Veterans Affairs medical centers and clinics.
  
  
  METHODS
  Forty-six women aged 45 years or older who had schizophrenia and 46 female control subjects who were frequency matched on age.
  
  
  RESULTS
  Twelve months of progress notes were reviewed for osteoporosis clinical services. In addition, smoking status, smoking cessation counseling, alcohol consumption, and fracture rates were compared between the groups. Overall, significantly fewer patients with schizophrenia (28 patients [61%]) received a clinical service for osteoporosis compared with the control group (37 patients [80%]). This difference was due to a significantly fewer number of patients with schizophrenia who received any osteoporosis agent (22 patients [48%]) compared with the control group (36 patients [78%]). Only 13 patients (28%) with schizophrenia received hormone replacement therapy compared with 25 control patients (54%).
  
  
  CONCLUSIONS
  Women with schizophrenia in three Midwest Veterans Affairs medical centers did not receive the same level of osteoporosis care as that of age-matched control patients. This was primarily due to a lower utilization of osteoporosis agents, specifically hormone replacement therapy. Further research is necessary to determine the reason for this difference. Clinicians should be aware of medical management issues in patients with major psychiatric diagnoses and, specifically, osteoporosis care of women with schizophrenia.
authors.affiliation: College of Pharmacy, University of Iowa, Iowa City, USA.
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Bishop
authors.forename: Bruce
authors.initials: B
authors.lastname: Alexander
authors.forename: Brian C
authors.initials: BC
authors.lastname: Lund
authors.forename: Teresa B
authors.initials: TB
authors.lastname: Klepser
mesh_terms: D000368:Aged; D005260:Female; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D010342:Patient Acceptance of Health Care / Q000523:psychology; D012189:Retrospective Studies; D012307:Risk Factors; D012559:Schizophrenia / Q000150:complications*; D012565:Schizophrenic Psychology